echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Studies have shown that antihypertensive drugs can improve the survival rate of colorectal cancer

    Studies have shown that antihypertensive drugs can improve the survival rate of colorectal cancer

    • Last Update: 2021-08-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    After reviewing the results of nearly 14,000 colorectal cancer patients, the researchers determined that ACE inhibitors, beta blockers, and thiazide diuretics were all associated with lower mortality


    Researchers emphasize that more research is needed to confirm the connection between antihypertensive drugs and better treatment outcomes


    Dr.


    About colorectal cancer

    Colorectal cancer is the third most common cancer in the United States


    Hypertension is common in patients with colorectal cancer, but there are few studies on the potential impact of antihypertensive drugs on the prognosis of patients


    Researchers have found that ACE inhibitors and thiazide diuretics seem to provide the most significant benefits for patient survival and prognosis, while calcium channel blockers do not seem to have similar benefits


    Patient adherence to blood pressure regimens is also important: The researchers wrote in a new scientific paper outlining their findings: “Our findings show that patients who started using these drugs after diagnosis of stage I, II, or III CRC, Compared with patients who did not use these drugs, there is an association between increased adherence (blood pressure) drugs and lower.


    Scientists are not sure whether the obvious benefits of antihypertensive drugs come from the drugs themselves or because they control the patient’s high blood pressure


    Researchers pointed out that recently there have been several clinical trials testing the potential effects of antihypertensive drugs on other cancers


    Balkrishnan said: "It is exciting that we can confirm that the results of Dr.


    This work was supported by the University of Virginia Cancer Center and Fundaño de Amparo à Pesquisa do Estado de São Paulo


    Journal Reference :

    1. Rajesh Balkrishnan, Raj P.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.